Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet

Journal of Hepatology

Volumn 38, Issue 6, 2003, Pages 762-769

  Sakaida, Isao ^a   Tsuchiya, Masako ^a   Kawaguchi, Kotarou ^a   Kimura, Teruaki ^a   Terai, Shuji ^a   Okita, Kiwamu ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carcinogenesis; Fibrosis; Herbal medicine; Preneoplastic lesion; TJ 135

Indexed keywords

AMINO ACID; CHOLINE; COLLAGEN TYPE 3; HERBACEOUS AGENT; INCHIN KO TO; INCHINKO TO; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROCOLLAGEN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL COUNT; DIET; DOSE RESPONSE; ENZYME ACTIVITY; HERBAL MEDICINE; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; RAT; STELLATE CELL;

EID: 0038578508     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00094-1     Document Type: Article

References (27)

1. Kiyosawa K, Tanaka E. Characteristics of hepatocellular carcinoma in Japan. Oncology 2002;62(Suppl. 1):5-7 (review).
2. McCaughan GW. Asian perspectives on viral hepatitis: hepatitis C virus infection. J Gastroenterol Hepatol 2000;15(Suppl.):G90-G93 (review).
3. Kobayashi H, Horikoshi K, Yamataka A, Lane GJ, Yamamoto M, Miyano T. Beneficial effect of a traditional herbal medicine (inchin-ko-to) in postoperative biliary atresia patients. Pediatr Surg Int 2001;17:386-389.
4. Onji M, Kikuchi T, Kojiro M, Yamashita Y, Ohta Y. Combined use of ursodeoxycholic acid and Inchin-ko-to in jaundiced patients with primary biliary cirrhosis. Wakan-Yaku 1990;7:161-167.
5. Yamamoto M, Ogawa K, Morita M, Fukuda K, Komatsu Y. The herbal medicine Inchin-ko-to inhibits liver cell apoptosis induced by transforming growth factor beta 1. Hepatology 1996;23:552-559.
6. Yamamoto M, Miura N, Ohtake N, Amagaya S, Ishige A, Sasaki H, et al. Genipin, a metabolite derived from the herbal medicine Inchin-ko-to, and suppression of Fas-induced lethal liver apoptosis in mice. Gastroenterology 2000;118:380-389.
7. Sakaida I, Matsumura Y, Akiyama S, Hayashi K, Ishige A, Okita K. Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 1998;28:298-306.
8. Sakaida I, Kubota M, Kayano K, Takenaka K, Mori K, Okita K. Prevention of fibrosis reduces enzyme-altered lesions in the rat liver. Carcinogenesis 1994;15:2201-2206.
9. Sakaida I, Matsumura Y, Kubota M, Kayano K, Takenaka K, Okita K. The prolyl 4-hydroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient L-amino acid-defined diet. Hepatology 1996;23:755-763.
10. Kayano K, Sakaida I, Uchida K, Okita K. Inhibitory effects of the herbal medicine Sho-saiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells. J Hepatol 1998;29:642-649.
11. Ueno T, Inuzuka S, Torimura T, Tamaki S, Koh H, Kin M, et al. Serum hyaluronate reflects hepatic sinusoidal capillarization. Gastroenterology 1993;105:475-481.
12. Ghoshal AK, Farber E. Biology of disease: choline deficiency, lipotrope deficiency and the development of liver disease including liver cancer: a new perspective. Lab Invest 1993;68:255-260.
13. Sakaida I, Hironaka K, Uchida K, Okita K. Iron chelator deferoxamine reduces preneoplastic lesions in liver induced by choline-deficient L-amino acid-defined diet in rats. Dig Dis Sci 1999;44:560-569.
14. Sakaida I, Hironaka K, Uchida K, Suzuki C, Kayano K, Okita K. Fibrosis accelerates the development of enzyme-altered lesions in the rat liver. Hepatology 1998;28:1247-1252.
15. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002;35:762-771.
16. Reeves HL, Friedman SL. Activation of hepatic stellate cells: a key issue in liver fibrosis. Front Biosci 2002 Apr 1;7:d808-d826.
17. Friedman SL. The cellular basis of hepatic fibrosis. N Engl J Med 1993;328:1828-1835.
18. Pinzani M, Romanelli RG, Magli S. Progression of fibrosis in chronic liver diseases: time to tally the score. J Hepatol 2001;34:764-767.
19. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000;279:G245-G249.
20. Rockey DC. Hepatic fibrogenesis and hepatitis C. Semin Gastrointest Dis 2000;11:69-83.
21. Wu J, Zern MA. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 2000;35:665-672.
22. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001;21:397-416.
23. Reeves HL, Dack CL, Peak M, Burt AD, Day CP. Stress-activated protein kinases in the activation of rat hepatic stellate cells in culture. J Hepatol 2000;32:465-472.
24. Schnabl B, Bradham CA, Bennett BL, Manning AM, Stefanovic B, Brenner DA. TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells. Hepatology 2001;34:953-963.
25. Pinzani M, Marra F, Carloni V. Signal transduction in hepatic stellate cells. Liver 1998;18:2-13.
26. Okuyama H, Shimahara Y, Kawada N, Seki S, Kristensen DB, Yoshizato K, et al. Regulation of cell growth by redox-mediated extracellular proteolysis of platelet-derived growth factor receptor beta. J Biol Chem 2001;276:28274-28280.
27. Nakano N. Morphogenesis of septa in hepatic fibrosis induced by choline deficiency in rats. Acta Pathol Jpn 1986;36:1643-1652.